Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAMP Signaling with [11C]-Rolipram PET Before/After Ketamine in MDD
NCT05522673Phase 1Terminated
- Sponsor
- National Institute of Mental Health
- Start
- Feb 2023
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by National Institute of Mental Health. Primary endpoint: Whole Brain Total Distribution Volume (VT) of [11C](R)-rolipram. Started Feb 2023; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05522673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522673.